Pain rockets on positive results; plans Remoxy resubmission
This article was originally published in Scrip
Executive Summary
Pain Therapeutics, which has struggled for years trying to get its investigational extended-release oral formulation of oxycodone, known as Remoxy, to the US market is ready to try again at the FDA, which has twice before rejected the drug.